Financial Ratios Exact Sciences Corporation
Equities
EXAS
US30063P1057
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
53.02 USD | +1.30% |
|
-0.93% | -5.64% |
Jun. 04 | Exact Sciences Corporation, Q1 2025 Earnings Call, May 01, 2025 | |
Jun. 03 | Exact Sciences Corporation Presents at 45th Annual William Blair Growth Stock Conference, Jun-03-2025 08:40 AM |
Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -8.63 | -7.41 | -6.01 | -3.04 | -1.93 | |||||
Return on Total Capital | -9.31 | -8.3 | -6.88 | -3.44 | -2.2 | |||||
Return On Equity % | -33.2 | -21.18 | -19.39 | -6.6 | -37.09 | |||||
Return on Common Equity | -33.2 | -21.18 | -19.39 | -6.6 | -37.09 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 76.24 | 74.04 | 72.44 | 73.83 | 69.55 | |||||
SG&A Margin | 71.85 | 85.8 | 78.68 | 65.54 | 60.87 | |||||
EBITDA Margin % | -28.07 | -28.76 | -20.31 | -4.09 | 0.84 | |||||
EBITA Margin % | -32.76 | -33.59 | -25.11 | -8.67 | -3.5 | |||||
EBIT Margin % | -39.03 | -38.96 | -29.79 | -12.35 | -6.95 | |||||
Income From Continuing Operations Margin % | -56.9 | -33.71 | -29.91 | -8.17 | -37.29 | |||||
Net Income Margin % | -56.9 | -33.71 | -29.91 | -8.17 | -37.29 | |||||
Net Avail. For Common Margin % | -56.9 | -33.71 | -29.91 | -8.17 | -37.29 | |||||
Normalized Net Income Margin | -28.12 | -23.89 | -19.21 | -7.39 | -4.06 | |||||
Levered Free Cash Flow Margin | -9.96 | 0.76 | -12.84 | 3.67 | 2.04 | |||||
Unlevered Free Cash Flow Margin | -11.07 | 1.04 | -12.6 | 4.16 | 2.65 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.35 | 0.3 | 0.32 | 0.39 | 0.44 | |||||
Fixed Assets Turnover | 2.53 | 2.6 | 2.57 | 2.91 | 3.28 | |||||
Receivables Turnover (Average Receivables) | 8.2 | 7.86 | 11.13 | 13.82 | 12.19 | |||||
Inventory Turnover (Average Inventory) | 4.6 | 4.65 | 5.15 | 5.32 | 5.8 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 3.82 | 2.76 | 2.38 | 2.32 | 2.15 | |||||
Quick Ratio | 3.6 | 2.42 | 1.93 | 1.91 | 1.76 | |||||
Operating Cash Flow to Current Liabilities | 0.24 | -0.2 | -0.54 | 0.3 | 0.29 | |||||
Days Sales Outstanding (Average Receivables) | 44.61 | 46.46 | 32.81 | 26.4 | 30.02 | |||||
Days Outstanding Inventory (Average Inventory) | 79.53 | 78.47 | 70.93 | 68.55 | 63.14 | |||||
Average Days Payable Outstanding | 29.33 | 40.08 | 44.33 | 42.29 | 35.21 | |||||
Cash Conversion Cycle (Average Days) | 94.81 | 84.85 | 59.41 | 52.66 | 57.94 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 62.02 | 70.87 | 80.75 | 81.6 | 115.55 | |||||
Total Debt / Total Capital | 38.28 | 41.48 | 44.68 | 44.93 | 53.61 | |||||
LT Debt/Equity | 52.35 | 70.11 | 79.72 | 78.94 | 103.67 | |||||
Long-Term Debt / Total Capital | 32.31 | 41.03 | 44.1 | 43.47 | 48.09 | |||||
Total Liabilities / Total Assets | 42.67 | 49.32 | 51.13 | 51.4 | 59.48 | |||||
EBIT / Interest Expense | -6.06 | -37 | -31.62 | -15.88 | -7.1 | |||||
EBITDA / Interest Expense | -4.09 | -25.29 | -19.28 | -2.9 | 2.4 | |||||
(EBITDA - Capex) / Interest Expense | -4.77 | -32.59 | -30.21 | -9.29 | -2.63 | |||||
Total Debt / EBITDA | -4.46 | -5.1 | -6.49 | -45.47 | 42.73 | |||||
Net Debt / EBITDA | 0.23 | -2.91 | -4.82 | -31.69 | 26.75 | |||||
Total Debt / (EBITDA - Capex) | -3.83 | -3.96 | -4.14 | -14.21 | -39.08 | |||||
Net Debt / (EBITDA - Capex) | 0.19 | -2.26 | -3.08 | -9.9 | -24.46 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 70.19 | 18.49 | 17.95 | 19.93 | 10.36 | |||||
Gross Profit, 1 Yr. Growth % | 72.39 | 15.06 | 15.41 | 22.23 | 8.88 | |||||
EBITDA, 1 Yr. Growth % | 246.76 | 21.38 | -16.69 | -75.85 | -122.57 | |||||
EBITA, 1 Yr. Growth % | 215.35 | 21.47 | -11.8 | -58.61 | -55.4 | |||||
EBIT, 1 Yr. Growth % | 240.4 | 18.3 | -9.82 | -50.26 | -37.9 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 910.24 | -27.68 | 4.68 | -67.26 | 403.97 | |||||
Net Income, 1 Yr. Growth % | 910.24 | -27.68 | 4.68 | -67.26 | 403.97 | |||||
Normalized Net Income, 1 Yr. Growth % | 225.7 | 4.97 | -5.15 | -53.86 | -39.36 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 777.36 | -36.21 | 1.71 | -67.95 | 393.27 | |||||
Accounts Receivable, 1 Yr. Growth % | 78.87 | -7.09 | -27.05 | 28.84 | 22.27 | |||||
Inventory, 1 Yr. Growth % | 49.48 | 13.8 | 12.63 | 7.79 | 27.38 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 2.6 | 27.75 | 10.26 | -1 | -2.69 | |||||
Total Assets, 1 Yr. Growth % | 40.49 | 35.73 | -6.85 | 3.93 | -8.39 | |||||
Tangible Book Value, 1 Yr. Growth % | -1.36K | -798.17 | 21.8 | -11.67 | -12.42 | |||||
Common Equity, 1 Yr. Growth % | 23.4 | 51.53 | -10.17 | 3.36 | -23.62 | |||||
Cash From Operations, 1 Yr. Growth % | -222.24 | -174.91 | 118.67 | -169.83 | 34.86 | |||||
Capital Expenditures, 1 Yr. Growth % | -62.54 | 108.62 | 57.96 | -42.09 | 9.5 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -0.44 | -106.53 | -2.08K | -133.39 | -38.78 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 7.89 | -111.13 | -1.52K | -139.58 | -29.69 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 81.15 | 42.01 | 18.22 | 18.94 | 15.05 | |||||
Gross Profit, 2 Yr. CAGR % | 83.46 | 40.84 | 15.23 | 18.77 | 16.12 | |||||
EBITDA, 2 Yr. CAGR % | 75.2 | 66.4 | 0.6 | -56.09 | -77.01 | |||||
EBITA, 2 Yr. CAGR % | 76.45 | 65.1 | 3.54 | -40.67 | -57.57 | |||||
EBIT, 2 Yr. CAGR % | 91.04 | 71.61 | 3.32 | -34.07 | -45.01 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 120.11 | 67.19 | -12.99 | -41.46 | 28.46 | |||||
Net Income, 2 Yr. CAGR % | 120.11 | 67.19 | -12.99 | -41.46 | 28.46 | |||||
Normalized Net Income, 2 Yr. CAGR % | 95.8 | 28.9 | -0.2 | -34.9 | -47.64 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 97.92 | 46.33 | -19.45 | -42.9 | 25.66 | |||||
Accounts Receivable, 2 Yr. CAGR % | 126.81 | 28.91 | -17.67 | -3.05 | 25.51 | |||||
Inventory, 2 Yr. CAGR % | 53.52 | 30.42 | 13.21 | 10.19 | 17.18 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 56.05 | 14.42 | 19.51 | 5.09 | -1.85 | |||||
Total Assets, 2 Yr. CAGR % | 79.77 | 38.09 | 12.44 | -1.61 | -2.43 | |||||
Tangible Book Value, 2 Yr. CAGR % | 7.79 | 323.5 | 190.14 | 3.32 | -12.04 | |||||
Common Equity, 2 Yr. CAGR % | 103.63 | 21.68 | 16.67 | -3.64 | -11.15 | |||||
Cash From Operations, 2 Yr. CAGR % | 40.7 | -4.31 | 27.98 | 23.57 | -2.96 | |||||
Capital Expenditures, 2 Yr. CAGR % | -34.52 | -11.32 | 81.53 | -4.36 | -20.37 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 4.58 | -79.43 | 13.87 | 7.64 | -55.45 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 8.04 | -69.09 | 25.94 | 6.97 | -48.06 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 77.65 | 57.25 | 33.49 | 18.79 | 16.01 | |||||
Gross Profit, 3 Yr. CAGR % | 82.3 | 57.04 | 31.79 | 17.52 | 13.61 | |||||
EBITDA, 3 Yr. CAGR % | 59.72 | 55.03 | 32.13 | -37.48 | -64.83 | |||||
EBITA, 3 Yr. CAGR % | 60.89 | 55.8 | 33.96 | -23.73 | -46.06 | |||||
EBIT, 3 Yr. CAGR % | 70.07 | 62.83 | 38.49 | -19.03 | -35.37 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 95.02 | 50.38 | 43.03 | -37.18 | 19.99 | |||||
Net Income, 3 Yr. CAGR % | 95.02 | 50.38 | 43.03 | -37.18 | 19.99 | |||||
Normalized Net Income, 3 Yr. CAGR % | 80.26 | 56.84 | 16.37 | -22.83 | -36.42 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 78.4 | 34.36 | 29.62 | -40.75 | 17.16 | |||||
Accounts Receivable, 3 Yr. CAGR % | 106.66 | 68.44 | 6.63 | -4.42 | 4.74 | |||||
Inventory, 3 Yr. CAGR % | 52.48 | 38.94 | 24.2 | 11.38 | 15.64 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 95.45 | 45.92 | 13.54 | 12.68 | 2.43 | |||||
Total Assets, 3 Yr. CAGR % | 101.88 | 63.69 | 21.1 | 9.53 | -3.93 | |||||
Tangible Book Value, 3 Yr. CAGR % | 14.12 | 18.37 | 178.61 | 94.67 | -2.22 | |||||
Common Equity, 3 Yr. CAGR % | 75.72 | 70.71 | 9.97 | 12.05 | -10.83 | |||||
Cash From Operations, 3 Yr. CAGR % | 23.92 | 14.04 | 26.04 | 4.58 | 27.23 | |||||
Capital Expenditures, 3 Yr. CAGR % | 9.9 | -3.29 | 7.5 | 24.04 | 0.05 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 16.16 | -53.67 | -5.71 | -23.68 | -10.82 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 20.36 | -49.28 | 10.79 | -14.38 | -7 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 106.79 | 77.83 | 50.94 | 40.63 | 25.78 | |||||
Gross Profit, 5 Yr. CAGR % | 137.85 | 89.05 | 51.74 | 40.44 | 23.81 | |||||
EBITDA, 5 Yr. CAGR % | 22.57 | 26.4 | 32.73 | -5.6 | -33.95 | |||||
EBITA, 5 Yr. CAGR % | 25.19 | 28.59 | 34.86 | 6.66 | -15 | |||||
EBIT, 5 Yr. CAGR % | 29.62 | 32.43 | 39.32 | 14.13 | -3.88 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 39.99 | 28.93 | 40.37 | 3.11 | 37.01 | |||||
Net Income, 5 Yr. CAGR % | 39.99 | 28.93 | 40.37 | 3.11 | 37.01 | |||||
Normalized Net Income, 5 Yr. CAGR % | 33.58 | 32.21 | 41.09 | 11.04 | -15.1 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 26.8 | 16.3 | 29.02 | -4.59 | 28.05 | |||||
Accounts Receivable, 5 Yr. CAGR % | 116.23 | 90.99 | 43.01 | 35.05 | 13.81 | |||||
Inventory, 5 Yr. CAGR % | 69.08 | 72.71 | 35.36 | 26.63 | 21.34 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 77.29 | 82.02 | 60.5 | 28.32 | 7.37 | |||||
Total Assets, 5 Yr. CAGR % | 68.37 | 77.72 | 59.75 | 33.54 | 11.08 | |||||
Tangible Book Value, 5 Yr. CAGR % | 17.67 | 25.82 | 20.66 | 11.87 | 75.39 | |||||
Common Equity, 5 Yr. CAGR % | 53.92 | 58.82 | 42.36 | 35.8 | 0.98 | |||||
Cash From Operations, 5 Yr. CAGR % | 0.37 | -4.7 | 25.53 | 17.76 | 13.52 | |||||
Capital Expenditures, 5 Yr. CAGR % | 26.22 | 55.67 | 34.63 | -3.72 | -4.66 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 9.07 | -30.76 | 23.08 | -7.54 | -29.36 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 11.38 | -26.29 | 22.64 | -5.97 | -17.66 |
- Stock Market
- Equities
- EXAS Stock
- Financials Exact Sciences Corporation
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions